ScholarIQanswers from OpenAlex
Lung Institute
InstitutionResearch output, impact & collaborations
Lung Institute is a institution indexed in ScholarIQ from OpenAlex.
What is known about Lung Institute?
ScholarIQrecord summary
Lung Institute is a research organisation in Dallas, US. OpenAlex records 16,268 works and 2,680,321 citations for it. 3,062 researchers list it as their most recent affiliation.
How many works does Lung Institute have?
ScholarIQindexed works
Lung Institute has 16,268 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Lung Institute have?
ScholarIQcitation count
Lung Institute has 2,680,321 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Lung Institute?
ScholarIQresearcher count
Lung Institute has 3,062 researchers in the ScholarIQ index.
What is the average h-index at Lung Institute?
ScholarIQavg h-index
Lung Institute has an average h-index of 83.4 in OpenAlex.
What is the ROR of Lung Institute?
ScholarIQror
The ROR for Lung Institute is on the source record.
What is the OpenAlex record for Lung Institute?
ScholarIQopenalex
The OpenAlex for Lung Institute is on the source record.
Who are the most-cited researchers behind Lung Institute?
ScholarIQtop researchers by citations
2
Jadwiga A. Wedzicha · Chronic Obstructive Pulmonary Disease (COPD) Research
640 works58,920 citationsWhat are the most-cited papers on Lung Institute?
ScholarIQmost cited works
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine, Robert P. Giugliano, Anthony Keech, Narimon Honarpour, Stephen D. Wiviott, Sabina A. Murphy, Julia Kuder, Huei Wang, Thomas Liu, Scott M. Wasserman, Peter Sever, Terje R. Pedersen
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Peter Sever, Björn Dahlöf, Neil R Poulter, Hans Wedel, Gareth Beevers, Mark J. Caulfield, Rory Collins, Sverre E. Kjeldsen, Arni Kristinsson, Gordon T. McInnes, Jesper Mehlsen, Markku S. Nieminen, Eoin OʼBrien, Jan Östergren
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, Rafael Díaz, Mark Lakshmanan, Prem Pais, Jeffrey L. Probstfield, Jeffrey S. Riesmeyer, Matthew C. Riddle, Lars Rydén, Denis Xavier, Charles Atisso, Leanne Dyal, Stephanie Hall, Rao Ps, G.C. Wong, Álvaro Avezum, Jan Basile, Namsik Chung, Ignacio Conget, William C. Cushman, Edward Franek, Nicolae Hâncu, M Hanefeld, Shaun Holt, Petr Janský, Mátyás Keltai, Fernando Laņas, Lawrence A. Leiter, Patricio López‐Jaramillo, Ernesto Muñoz, Valdis Pīrāgs, Nana Pogosova, Peter Raubenheimer, Jonathan E. Shaw, Wayne Huey‐Herng Sheu, Theodora Temelkova‐Kurktschiev, Mercedes Abella, Andrea Alebuena, Sandra Almagro, Eduardo Amoroso, Paula Anadon, Elizabeth Andreu, Guillermo Aristimuño, Maria Arzadun, María Antonietta Barbieri, Raúl Barcudi, Ines Bartolacci, Gabriel Bolobanich, Anselmo P. Bordonava, Miguel Bustamante Labarta, B. Bustos, Alberto Caccavo, Alejandra Camino, María del Rocío Cantero, Maria Carignano, Luis R Cartasegna, Marcela Cipullo, Víctor Commendatore, Victoria Conosciuto, Osvaldo Costamagna, Claudia A. Crespo, Jose Cuello, Carlos Alberto Cuneo, Sandra Cusimano, Sofia Dean, Claudio Fabián Dituro, Andrea Domínguez, Miguel Farah, Alberto Fernandez, Florencia Fernandez, Adriana Cristina Ferrari, Patricia Flammia, José Antonio Fuentealba, Karina Beatriz Gallardo, C. Perez Garcia, Ruben Garcia Duran, Marcelo Garrido, Rodolfo Gavícola, Claudio Gerbaudo, Graciela Gilli, Ana Paula Giotto, Pedro Godoy Bolzán, Oscar Gómez Vilamajó, Fernando Guerlloy, Cristian Guridi, Narcisa Gutierrez Garrido, Eduardo Hasbani, Sonia Hermida, Miguel Hominal, Adrian D. Hrabar, Adrián Ingaramo, Alejandra Izzicupo, Mario Krynski, Mariana Lagrutta, Paulina Virginia Lanchiotti, Maria Langhe, Veronica Leonard, Javier Llanos, Ricardo López Santi
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
Björn Dahlöf, Peter Sever, Neil R Poulter, Hans Wedel, DG Beevers, Mark J. Caulfield, Rory Collins, Sverre E. Kjeldsen, Arni Kristinsson, Gordon T. McInnes, Jesper Mehlsen, Markku S. Nieminen, Eoin OʼBrien, Jan Östergren
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
John W. Eikelboom, Stuart J. Connolly, Jackie Bosch, Gilles R. Dagenais, Robert G. Hart, Olga Shestakovska, Rafael Díaz, Marco Alings, Eva Lonn, Sonia S. Anand, Petr Widimský, Masatsugu Hori, Álvaro Avezum, Leopoldo Soares Piegas, Kelley R. Branch, Jeffrey L. Probstfield, Deepak L. Bhatt, Jun Zhu, Yan Liang, Aldo P. Maggioni, Patricio López‐Jaramillo, Martin O’Donnell, Ajay K. Kakkar, Keith A.A. Fox, Alexander Parkhomenko, Georg Ertl, Stefan Störk, Mátyás Keltai, Lars Rydén, Nana Pogosova, Antonio L Dans, Fernando Laņas, Patrick Commerford, Christian Torp‐Pedersen, Tomek J. Guzik, Peter Verhamme, Dragoş Vinereanu, Jae‐Hyung Kim, Andrew M. Tonkin, Basil S. Lewis, Camilo Félix, Khalid Yusoff, Philippe Gabríel Steg, Kaj Metsärinne, Nancy Cook Bruns, Frank Misselwitz, Edmond Chen, Darryl P. Leong, Salim Yusuf
How much of the research on Lung Institute is open access?
ScholarIQopen access share
67%OPEN ACCESS